Tim McCarthy, chairman of ImmuPharma PLC (LON:IMM), tells Proactive the last patient has completed dosing within the 52-week, randomised, double-blinded, Phase III clinical trial of Lupuzor?,,?, their lead programme for the potential breakthrough compound for Lupus, the life threatening auto-immune disease.
He adds that 200 patients have now been successfully recruited and dosed, with top line results remaining on track to be reported in the first quarter of 2018.
Meet Netscientific PLC, discoverIE Group plc, Itaconix Plc and Realm Therapeutics plc at our event, London, 25 January 2018.Register here >>